Abstract 634P
Background
CTS2190 could specifically inhibit type I protein arginine methyltransferases (PRMTs) and significantly reduce intra-tumor asymmetric dimethylarginine (ADMA) level and oncogenic proliferation by epigenetic modulation, RNA splicing, DNA damage as well as remarkable cancer immune activation in various solid and/or hematological cancers. Here we report the dose escalation results from an ongoing first-in-human phase I/II study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of CTS2190 in patients (pts) with advanced solid tumors.
Methods
Eligible pts were enrolled in escalating dose cohorts (60 to 240 mg) administered orally until progression or unacceptable toxicity. The accelerated titration combined with Bayesian optimal interval (BOIN) design was used as the dose escalation schedule.
Results
As of Apr 2, 2024, 15 pts including 10 non-small cell lung cancer (NSCLC), 1 colorectal cancer (CRC),1 triple-negative breast cancer (TNBC), 2 head and neck squamous cell carcinoma (HNSCC) and 1 esophageal squamous cell carcinoma (ESCC) received CTS2190 treatment. Among them, 9 pts received ≥3 lines of prior therapy. Treatment-related adverse events (TRAEs) of ≥Grade 3 were platelet count decreased (33.3%), amylase increased (6.7%) and blood creatine phosphokinase increased (6.7%). Dose-limiting toxicity (DLT) was observed in 1 pt (in 240 mg) who continued treatment after dose reduction. No TRAEs led to treatment discontinuation or death. Of the 10 response-evaluable pts (>60 mg), the objective response rate (ORR) and disease control rate (DCR) were 20.0% and 70.0% respectively. In the subset of NSCLC pts, the ORR and DCR were 40.0% and 60.0% respectively. Exposure of CTS2190 increased proportionally with increasing dose. Time- and dose-dependent pharmacodynamics (PD) changes in circulating free ADMA, monomethylarginine (MMA) and symmetric dimethylarginine (SDMA) were also observed.
Conclusions
CTS2190 was well tolerated and showed encouraging antitumor activities in advanced and/or metastatic solid tumors, including NSCLC, TNBC, HNSCC and ESCC. Further investigation of CTS2190 in larger pts population is ongoing including biomarker exploration.
Clinical trial identification
NCT06224387.
Editorial acknowledgement
Legal entity responsible for the study
CytosinLab Therapeutics Co., Ltd.
Funding
CytosinLab Therapeutics Co., Ltd.
Disclosure
J. Miao, Y. Mi, S. Xing, H. Wu: Financial Interests, Personal and Institutional, Full or part-time Employment: CytosinLab Therapeutics Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01